Fax: (904) 953-1412
Article first published online: 17 OCT 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 12, pages 3014–3025, 15 June 2012
How to Cite
Perez, E. A. and Spano, J.-P. (2012), Current and emerging targeted therapies for metastatic breast cancer. Cancer, 118: 3014–3025. doi: 10.1002/cncr.26356
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, are fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development.
Writing and editorial assistance was provided by Alyssa Tippens, PhD, of MedErgy, which was contracted by Boehringer Ingelheim Pharmaceuticals, Inc., for these services.
- Issue published online: 4 JUN 2012
- Article first published online: 17 OCT 2011
- Manuscript Accepted: 10 MAY 2011
- Manuscript Revised: 27 APR 2011
- Manuscript Received: 8 FEB 2011
- metastatic breast cancer;
- targeted therapies;
- epidermal growth factor receptor;
- human epidermal growth factor receptor 2;
- multitargeted tyrosine kinase inhibitors
The success of endocrine therapies for hormone receptor-positive breast cancer and trastuzumab and lapatinib for targeting human epidermal growth factor receptor 2 (HER2)-positive tumors has paved the way for the clinical development of several other metastatic breast cancer (MBC)-targeted therapies. Although the benefit of the anti-VEGF (vascular endothelial growth factor) monoclonal antibody bevacizumab in the MBC setting has become a topic of debate, clinical trial results are accumulating, and phase 3 evaluations are ongoing for newer HER2-targeted agents (pertuzumab and trastuzumab-maytansine immunoconjugate) and VEGF-targeted agents (aflibercept), as well as dual, epidermal growth factor receptor/HER2-targeted agents (afatinib [BIBW 2992] and neratinib), multitargeted tyrosine kinase inhibitors (sunitinib and pazopanib), and mammalian target of rapamycin (everolimus) and poly (ADP-ribose) polymerase 1 inhibitors (iniparib, olaparib). These agents as well as other novel classes of anticancer agents are being tested in clinical trials with the potential of addressing unmet therapeutic needs in the MBC patient population. Cancer 2012;118: 3014–25. © 2011 American Cancer Society.